高级检索

SLC13A5驱动的代谢−炎症轴在代谢性疾病、癌症及神经系统疾病中的作用及研究进展

Roles and research progress of the SLC13A5-driven metabolic-inflammatory axis in metabolic diseases, cancers and neurological disorders

  • 摘要: SLC13A5(solute carrier family 13 member 5)是介导胞外柠檬酸跨膜摄取的重要转运蛋白,通过调控胞质柠檬酸及乙酰辅酶A水平,参与能量代谢、脂质合成、炎症反应和神经元稳态维持。本文聚焦SLC13A5驱动的代谢–炎症轴,系统综述其在多种疾病中的作用机制及靶向干预研究进展。SLC13A5介导的柠檬酸代谢重编程可通过影响脂质合成、氧化应激及炎症信号传递等,形成连接代谢紊乱与炎症反应的调控网络。在代谢性疾病中,SLC13A5表达上调可促进肝脏脂质从头合成并加重胰岛素抵抗,推动代谢功能障碍相关脂肪性肝病(MASLD)向炎症及纤维化阶段进展;在炎症相关疾病中,SLC13A5表达上调可通过增强柠檬酸代谢通量促进炎症介质生成,并放大炎症反应;在癌症中,SLC13A5参与代谢重编程和炎症性肿瘤微环境维持,从而支持肿瘤细胞生长与增殖;在神经系统中,SLC13A5功能缺失或表达异常可扰乱神经元能量代谢、神经递质平衡及神经网络功能,导致癫痫和神经发育相关疾病。本文进一步总结了小分子抑制剂、反义寡核苷酸及基因替代治疗等SLC13A5靶向策略,并讨论了组织选择性、中枢安全风险、物种差异及递送效率低等转化挑战,为SLC13A5相关疾病的机制研究和精准治疗提供理论依据。

     

    Abstract: SLC13A5 (solute carrier family 13 member 5) is an important transporter that mediates the transmembrane uptake of extracellular citrate. By regulating cytosolic citrate and acetyl-CoA levels, SLC13A5 participates in energy metabolism, lipid synthesis, inflammatory responses, and the maintenance of neuronal homeostasis. This review focuses on the SLC13A5-driven metabolic–inflammatory axis and systematically summarizes its roles and underlying mechanisms in various diseases, as well as recent advances in targeted interventions. SLC13A5-mediated citrate metabolic reprogramming affects lipid synthesis, oxidative stress, and inflammatory signaling, thereby establishing a regulatory network that links metabolic dysfunction with inflammatory responses. In metabolic diseases, upregulated SLC13A5 promotes hepatic de novo lipogenesis, exacerbates insulin resistance, and drives the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) toward inflammatory and fibrotic stages. In inflammation-related diseases, increased SLC13A5 expression enhances citrate metabolic flux, promotes the production of inflammatory mediators, and amplifies inflammatory responses. In cancer, SLC13A5 contributes to metabolic reprogramming and the maintenance of an inflammatory tumor microenvironment, thereby supporting tumor cell growth and proliferation. In the nervous system, loss of SLC13A5 function or abnormal SLC13A5 expression disrupts neuronal energy metabolism, neurotransmitter homeostasis, and neural network function, leading to epilepsy and neurodevelopmental disorders. This review further summarizes SLC13A5-targeted strategies, including small-molecule inhibitors, antisense oligonucleotides, and gene replacement therapy, and discusses the translational challenges such as tissue selectivity, central nervous system safety risks, species differences, and limited delivery efficiency. This review provides a theoretical basis for investigating the mechanisms of SLC13A5-related diseases and developing precision therapeutic strategies.

     

/

返回文章
返回